Merck and Moderna just dropped a blockbuster in cancer treatment: their personalized mRNA vaccine combo slashed recurrence and death risk in high-risk patients, outperformed Keytruda alone, sent Merck’s stock soaring over 11%, and pushed the pharma giant to a new 52-week high—proof that precision medicine is rewriting the playbook for oncology.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
